Literature DB >> 30788234

The evolving toxicity profile of SBRT for lung cancer.

Marcher Thompson1, Kenneth E Rosenzweig1.   

Abstract

Stereotactic body radiation therapy (SBRT) is an effective and well tolerated treatment for early stage non-small cell lung cancer (NSCLC). The high doses used in thoracic SBRT can sometimes cause adverse effects ranging from mild fatigue and transient esophagitis to fatal events such as pneumonitis or hemorrhage. Efforts continue to expand in both the utility of this technique as well as our understanding of the mechanisms of the adverse effects it can cause. In this review, we discuss the current literature regarding the potential mechanisms, dosimetric constraints and toxicities associated with SBRT alone and in conjunction with definitive chemoradiotherapy and immunotherapy. As the use of SBRT expands to these spheres, we examine the available recommendations for mitigating potential associated treatment related toxicities.

Entities:  

Keywords:  Lung cancer; immunotherapy; radiation therapy; stereotactic body radiation therapy (SBRT); toxicity

Year:  2019        PMID: 30788234      PMCID: PMC6351399          DOI: 10.21037/tlcr.2018.10.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  11 in total

1.  Ex Vivo Irradiation of Lung Cancer Stem Cells Identifies the Lowest Therapeutic Dose Needed for Tumor Growth Arrest and Mass Reduction In Vivo.

Authors:  Caterina Puglisi; Raffaella Giuffrida; Giuseppina Borzì; Salvatore Illari; Francesco Paolo Caronia; Paolo Di Mattia; Cristina Colarossi; Gianluca Ferini; Emanuele Martorana; Giovanni Sette; Adriana Eramo; Aurelio Lorico; Alfio Di Grazia; Stefano Forte
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

2.  Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration.

Authors:  Katie Jasper; Baochang Liu; Robert Olson; Quinn Matthews
Journal:  Adv Radiat Oncol       Date:  2021-07-03

Review 3.  Cellular Senescence in the Lung: The Central Role of Senescent Epithelial Cells.

Authors:  Christine Hansel; Verena Jendrossek; Diana Klein
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

4.  Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease.

Authors:  Yuanjun Liu; Yaoyao Zhu; Ran Wu; Min Hu; Lingnan Zhang; Qingren Lin; Denghu Weng; Xiaojiang Sun; Yu Liu; Yaping Xu
Journal:  Transl Lung Cancer Res       Date:  2020-12

5.  Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases.

Authors:  Ben Man Fei Cheung; Kin Sang Lau; Victor Ho Fun Lee; To Wai Leung; Feng-Ming Spring Kong; Mai Yee Luk; Kwok Keung Yuen
Journal:  Radiat Oncol J       Date:  2021-10-26

6.  CT-guided palladium-103 seed brachytherapy for metastatic adenoid cystic carcinoma: a retrospective study to assess initial safety and effectiveness of percutaneous CT fluoroscopy-guided permanent seed brachytherapy.

Authors:  Stephen W Doggett; Kelly W Elliott; Shigeru Chino; Kevin Burns; Todd Lempert
Journal:  J Contemp Brachytherapy       Date:  2021-10-29

7.  Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.

Authors:  Roman O Kowalchuk; Michael R Waters; Martin Richardson; Kelly Spencer; James M Larner; Charles R Kersh
Journal:  Thorac Cancer       Date:  2020-05-29       Impact factor: 3.500

8.  Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience.

Authors:  Guangjin Chai; Yutian Yin; Xiaoying Zhou; Qilong Hu; Bo Lv; Zhaohui Li; Mei Shi; Lina Zhao
Journal:  Transl Lung Cancer Res       Date:  2020-08

9.  Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.

Authors:  Hidehito Horinouchi; Shinji Atagi; Satoshi Oizumi; Kadoaki Ohashi; Tomohiro Kato; Toshiyuki Kozuki; Masahiro Seike; Takashi Sone; Tomotaka Sobue; Takaaki Tokito; Hideyuki Harada; Tadashi Maeda; Tadashi Mio; Ikue Shirosaka; Kana Hattori; Eisei Shin; Haruyasu Murakami
Journal:  Cancer Med       Date:  2020-07-30       Impact factor: 4.452

10.  Impact of high-dose rate radiotherapy on B and natural killer (NK) cell polarization in peripheral blood mononuclear cells (PBMCs) via inducing non-small cell lung cancer (NSCLC)-derived exosomes.

Authors:  Qian-Qian Lei; Jiang-Dong Sui; Fu Jin; Huan-Li Luo; Juan-Juan Shan; Li Tang; Ying Wang; Yong-Zhong Wu
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.